title: A prospective study of p53 expression and its correlation with clinical response of radiotherapy in nasopharyngeal carcinoma.
abstract: OBJECTIVE
  Nasopharyngeal carcinoma (NPC) is a common malignant neoplasm of the head and neck that occurs in people in the southeastern Asian area, including Taiwan. The significant association of p53 expression in NPC suggested that p53 overexpression seemed to occur at an early stage in the development of NPC. Alterations of p53 status were probably the most commonly encountered in head and neck carcinomas, and there was extensive evidence that p53 status might determine tumor response to therapy. Ionizing radiation was studied extensively for the relationship between its damaging effect and p53 status in human cancer cells.
  
  
  METHODS
  This study was carried out to investigate whether there was any correlation between overexpression of p53 protein and locoregional tumor response in patients with NPC treated with 7000 cGy of radiotherapy.
  
  
  METHODS
  Sixty-eight patients (50 males, 18 females) with NPC who were diagnosed and treated with radiotherapy were studied prospectively. Before they had received a radiation dose of 7000 cGy in 35 fractions, five fractions a week, p53 status from a nasopharyngeal biopsy was studied using immunohistochemical staining (IHC).
  
  
  RESULTS
  The locoregional response rate of primary tumor was analyzed statistically. Forty-seven patients (69.1%) showed positive p53 staining in their tumors. There were 5 positive stains in 6 squamous cell carcinomas (SCC; 83.3%), 34 positive in 53 non-keratinizing carcinomas (NKC; 64.2%), and 8 positive in 9 undifferentiated carcinomas (UC; 88.9%). The mean ages for patients with three different histopathologies were 48.5, 46.1, and 61.1 years. There were 8 patients (7 positive stains, 1 negative stain) with residual tumor after radiotherapy and all were NKC (6 males, 2 females). Therefore, the clinical response rate of primary tumor was 85.1% in positive p53 immunostaining (40 of 47 cases), 95.2% in those with no immunostaining (20 of 21 cases); the former was poorer in locoregional tumor response than the latter, but there was no significant difference (P > .05, chi2 test).
  
  
  CONCLUSIONS
  We conclude that there is no statistically significant correlation in locoregional response of primary tumor between p53 overexpression and radiotherapy in patients with NPC (P > .05, Fisher exact test).
authors.affiliation: Department of Otorhinolaryngology, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan, Republic of China.
authors.forename: K Y
authors.initials: KY
authors.lastname: Ho
authors.forename: W R
authors.initials: WR
authors.lastname: Kuo
authors.forename: C Y
authors.initials: CY
authors.lastname: Chai
authors.forename: S M
authors.initials: SM
authors.lastname: Tsai
authors.forename: S H
authors.initials: SH
authors.lastname: Sheu
authors.forename: S C
authors.initials: SC
authors.lastname: Wu
authors.forename: K H
authors.initials: KH
authors.lastname: Juan
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000911:Antibodies, Monoclonal; D002277:Carcinoma / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy; D016009:Chi-Square Distribution; D019583:Dose Fractionation, Radiation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D012074:Remission Induction; D012737:Sex Factors; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D000911:Antibodies, Monoclonal; D016159:Tumor Suppressor Protein p53